vorasidenib
servier
['indigo', 'vorasidenib']
 asco 2023 prominent physician, #timothycloughesymd, from , shares a summary of the groundbreaking #indigo trial results at #asco23, efficacy of vorasidenib, an idh inhibitor, in patients with idh-mutant low-grade #glioma. 
Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.